IDXX

IDEXX Laboratories, Inc. (IDXX) | Rumor.io

IDEXX Laboratories

IDXX

Attention (50-day avg)0%

Attention rank (50-day avg)#1,644

Bullish sentiment (50-day avg)86%

Price to earnings ratio36.5

Market capitalization41.7B

Earnings per share14.2

Dividend yield (TTM)—

Revenue (annual)4.3B

Net income (annual)1.1B

Social

What share of all stock conversation is about IDXX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% -0.01	0.01% +0

Aug 4

IDXX reported Q2 FY2026 revenue of $1.217B, a 10% increase YoY, and raised its FY2026 revenue guidance to $4.70B-$4.75B.
The company achieved an 18% increase in EPS, with a reported GAAP EPS of $4.27, and updated its FY2026 EPS guidance to $14.69-$14.94.
IDXX expanded its operating margin by 140 basis points to 35.0%, driven by the company's "Technology for Life" strategy and continued innovation across its platforms.

Generated by AI

Sentiment

Of the messages about IDXX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	87.36% +1.51	93.47% +6.24
Bearish	—	—	12.64% -1.51	6.53% -6.24

Mar 7

IDXX has a strong moat due to its installed base of lab equipment in vet clinics, creating a high-margin razor/blade dynamic.
The company benefits from pet spending trends, which are less correlated with recessions and have continued to grow.
IDXX has a durable business model, with solid margins and steady instrument replacement cycles, supported by its leading diagnostics market position.

Generated by AI

Topics

Of the messages about IDXX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	0%	50.69%
Macro	—	—	41.03%	8.38%
Technical Analysis	—	—	0%	10.94%
Analysts	—	—	41.03%	6.5%
Earnings	—	—	17.95%	23.49%
Controversies	—	—	0%	0%

Earnings· Feb 2

IDXX reported Q4'25 earnings with $1.09B revenue, beating estimates by 2%, and $3.08 EPS, missing estimates by 5%.
The company guided FY26 EPS to $14.29-$14.80, and revenue to $4.63-$4.72B, both near estimates.
IDXX's strong CAG Diagnostics recurring revenue and record instrument placements drove solid margin expansion, but shares dipped 1.5% despite the beat.

Analysts· Aug 23

Bank of America Corporation upgraded IDXX to Buy from Neutral, maintaining a $175 price target, citing underappreciated runway in diagnostic utilization and upside to long-term targets.
BAML and Canaccord Genuity also upgraded IDXX to Buy, with the latter reiterating a $180 price target, citing the company's undervalued stock and potential for diagnostic growth.
Stifel Nicolaus and Bank of America Corporation reiterated a Buy rating for IDXX, with the latter citing a 5-year DCF implying the stock is undervalued.

Announcements· Feb 2

IDXX reported Q4 revenue of $1.091B, up 14% YoY, with CAG Diagnostics recurring revenue up 12% YoY.
The company's FY26 guidance is for revenue of $4.632B-$4.720B and EPS of $14.29-$14.80.
IDXX's Q4 growth was driven by the adoption of the inVue Dx platform, with 1,900+ placements and record instruments.

Generated by AI

Community

Of the messages about IDXX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	100%	71.81%	19.88%
Newcomers	—	0%	28.19%	80.12%

Regulars· Feb 2

IDEXX Laboratories' Q4 2025 earnings showed revenue of $1.09B, a 14% increase from the prior year period, driven by strong Companion Animal Group (CAG) Diagnostics recurring revenue and record instrument placements.
The company's adjusted EPS for Q4 2025 was $2.92, beating the expected $2.94, and the net income was $248M.
IDEXX Laboratories guided FY26 EPS to be between $14.29 and $14.80, with a revenue guidance of $4.63B to $4.72B, both higher than the expected values.

Newcomers· Aug 4

IDEXX Laboratories reported Q2 revenue of $1.217B, a 10% increase from the same period last year, and raised FY2026 EPS guidance midpoint by $0.14 to $14.69-$14.94.
The company's Q2 EPS beat estimates, with a reported EPS of $4.27, a 18% increase from the same period last year.
IDEXX's FY2026 EPS guidance was raised, with a midpoint of $14.69-$14.94, indicating a positive outlook for the company's future earnings.

Generated by AI

News

IDEXX Laboratories Inc. stock outperforms competitors on strong trading day

1d agoMarketWatch

IDEXX Laboratories Inc. stock outperforms competitors on strong trading day

4d agoMarketWatch

IDEXX Laboratories Inc. stock underperforms Thursday when compared to competitors

5d agomarketwatch.com

IDEXX Laboratories Inc. stock outperforms competitors on strong trading day

7d agoMarketWatch

IDEXX Laboratories Highlights Diagnostic Pipeline, Reaffirms Long-Term Growth Targets

IDEXX Laboratories (NASDAQ:IDXX) executives highlighted the company’s diagnostic innovation pipeline, recurring-revenue growth and commercial investments during the Morgan Stanley Global Healthcare Conference, while reaffirming confidence in its long-term growth framework despite continued pressure

9d agoYahoo Finance

IDEXX Highlights Diagnostics Growth Drivers, Cancer Testing at Morgan Stanley Conference

IDEXX Laboratories (NASDAQ:IDXX) executives reiterated the company’s long-term growth framework at the Morgan Stanley Global Healthcare Conference, citing demand for veterinary diagnostics, product innovation, commercial investments and recurring-revenue economics as key drivers. Chief Executive Of

9d agoYahoo Finance

Also Discussed

Investors talking about IDXX also mention

#	Name	Attention
1	Zoetis Inc. Class A Common StockZTS	0.03%+0.02
2	HSKA - Heska Corporation	——
3	PETQ - PetIQ, Inc.	——
4	Elanco Animal Health IncELAN	0%new
5	Freshpet, Inc.FRPT	0%0
6	Revvity Inc.RVTY	0%0
7	Tyler Technologies Inc.TYL	0%0
8	Mettler-Toledo International Inc.MTD	0%new
9	Roper Technologies Inc.ROP	0%+0
10	Henry Schein, Inc.HSIC	0%0

IDEXX Laboratories, Inc.

Healthcare
Diagnostics & Research

IDEXX Laboratories, Inc. is a global diagnostics and software company focused on animal health, water quality, and agricultural testing. IDEXX Laboratories, Inc. develops and supplies in-clinic veterinary diagnostic instruments, consumable test kits, reference laboratory services, and practice management software that help veterinarians diagnose and monitor companion animals. The company also provides testing solutions for livestock, poultry, and dairy producers, along with water microbiology products used to assess drinking water safety and quality. Its product portfolio is built around recurring consumables, laboratory workflows, and integrated software tools that support everyday clinical and operational decisions. IDEXX Laboratories, Inc. serves veterinary practices, animal health professionals, utilities, and food-production customers across global markets, making it an important provider of diagnostic infrastructure in the broader healthcare and environmental testing ecosystem.

Website

Location

One IDEXX Drive

Westbrook, ME, 04092

United States

Social

What share of all stock conversation is about IDXX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% -0.01	0.01% +0

Aug 4

IDXX reported Q2 FY2026 revenue of $1.217B, a 10% increase YoY, and raised its FY2026 revenue guidance to $4.70B-$4.75B.
The company achieved an 18% increase in EPS, with a reported GAAP EPS of $4.27, and updated its FY2026 EPS guidance to $14.69-$14.94.
IDXX expanded its operating margin by 140 basis points to 35.0%, driven by the company's "Technology for Life" strategy and continued innovation across its platforms.

Generated by AI

Sentiment

Of the messages about IDXX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	87.36% +1.51	93.47% +6.24
Bearish	—	—	12.64% -1.51	6.53% -6.24

Mar 7

IDXX has a strong moat due to its installed base of lab equipment in vet clinics, creating a high-margin razor/blade dynamic.
The company benefits from pet spending trends, which are less correlated with recessions and have continued to grow.
IDXX has a durable business model, with solid margins and steady instrument replacement cycles, supported by its leading diagnostics market position.

Generated by AI

Topics

Of the messages about IDXX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	0%	50.69%
Macro	—	—	41.03%	8.38%
Technical Analysis	—	—	0%	10.94%
Analysts	—	—	41.03%	6.5%
Earnings	—	—	17.95%	23.49%
Controversies	—	—	0%	0%

Earnings· Feb 2

IDXX reported Q4'25 earnings with $1.09B revenue, beating estimates by 2%, and $3.08 EPS, missing estimates by 5%.
The company guided FY26 EPS to $14.29-$14.80, and revenue to $4.63-$4.72B, both near estimates.
IDXX's strong CAG Diagnostics recurring revenue and record instrument placements drove solid margin expansion, but shares dipped 1.5% despite the beat.

Analysts· Aug 23

Bank of America Corporation upgraded IDXX to Buy from Neutral, maintaining a $175 price target, citing underappreciated runway in diagnostic utilization and upside to long-term targets.
BAML and Canaccord Genuity also upgraded IDXX to Buy, with the latter reiterating a $180 price target, citing the company's undervalued stock and potential for diagnostic growth.
Stifel Nicolaus and Bank of America Corporation reiterated a Buy rating for IDXX, with the latter citing a 5-year DCF implying the stock is undervalued.

Announcements· Feb 2

IDXX reported Q4 revenue of $1.091B, up 14% YoY, with CAG Diagnostics recurring revenue up 12% YoY.
The company's FY26 guidance is for revenue of $4.632B-$4.720B and EPS of $14.29-$14.80.
IDXX's Q4 growth was driven by the adoption of the inVue Dx platform, with 1,900+ placements and record instruments.

Generated by AI

Community

Of the messages about IDXX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	100%	71.81%	19.88%
Newcomers	—	0%	28.19%	80.12%

Regulars· Feb 2

IDEXX Laboratories' Q4 2025 earnings showed revenue of $1.09B, a 14% increase from the prior year period, driven by strong Companion Animal Group (CAG) Diagnostics recurring revenue and record instrument placements.
The company's adjusted EPS for Q4 2025 was $2.92, beating the expected $2.94, and the net income was $248M.
IDEXX Laboratories guided FY26 EPS to be between $14.29 and $14.80, with a revenue guidance of $4.63B to $4.72B, both higher than the expected values.

Newcomers· Aug 4

IDEXX Laboratories reported Q2 revenue of $1.217B, a 10% increase from the same period last year, and raised FY2026 EPS guidance midpoint by $0.14 to $14.69-$14.94.
The company's Q2 EPS beat estimates, with a reported EPS of $4.27, a 18% increase from the same period last year.
IDEXX's FY2026 EPS guidance was raised, with a midpoint of $14.69-$14.94, indicating a positive outlook for the company's future earnings.

Generated by AI

IDEXX Laboratories

Social

Aug 4

Mar 7

Earnings· Feb 2

Analysts· Aug 23

Announcements· Feb 2

Regulars· Feb 2

Newcomers· Aug 4

IDEXX Laboratories Inc. stock outperforms competitors on strong trading day

IDEXX Laboratories Inc. stock outperforms competitors on strong trading day

IDEXX Laboratories Inc. stock underperforms Thursday when compared to competitors

IDEXX Laboratories Inc. stock outperforms competitors on strong trading day

IDEXX Laboratories Highlights Diagnostic Pipeline, Reaffirms Long-Term Growth Targets

IDEXX Highlights Diagnostics Growth Drivers, Cancer Testing at Morgan Stanley Conference

Also Discussed

IDEXX Laboratories, Inc.

Company Information

Location

IDEXX Laboratories Inc. stock outperforms competitors on strong trading day

IDEXX Laboratories Inc. stock outperforms competitors on strong trading day

IDEXX Laboratories Inc. stock underperforms Thursday when compared to competitors

IDEXX Laboratories Inc. stock outperforms competitors on strong trading day

IDEXX Laboratories Highlights Diagnostic Pipeline, Reaffirms Long-Term Growth Targets

IDEXX Highlights Diagnostics Growth Drivers, Cancer Testing at Morgan Stanley Conference

Also Discussed

Social

Aug 4

Mar 7

Earnings· Feb 2

Analysts· Aug 23

Announcements· Feb 2

Regulars· Feb 2

Newcomers· Aug 4